In particular, we need to stress that when we discuss information regarding the status of our KRYSTEXXA and marketing efforts, and additional plans related there too, market demand and reimbursement for KRYSTEXXA, our review of the refractory chronic gout or RCG market size, our beliefs with respect to the ability to gain and maintain market acceptance of KRYSTEXXA by physicians, patients, healthcare payers and others in the medical community, our marketing authorization application or MAA pending before the European medicines agency and our intended pursuit of expanded clinical utility for KRYSTEXXA. No inference of overall success of these matters can be implied as they are subject to a number of risks and uncertainties.We encourage you to review our press release dated August 8, 2012 and our company’s filings with the Securities and Exchange Commission including without limitation, our Form 10-Q which will be filed on or before November 9, 2012. Each of these contains important factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.